Other grades of this product :
| Product Name: | INF39 | | Synonyms: | INF39;Ethyl 2-(2-chlorobenzyl)acrylate;CS-2508;INF-39;INF 39;INF39;Benzenepropanoic acid, 2-chloro-α-methylene-, ethyl ester;INF39 >=98% (HPLC) | | CAS: | 866028-26-4 | | MF: | C12H13ClO2 | | MW: | 224.68 | | EINECS: | | Product Categories: | | Mol File: | 866028-26-4.mol |
| INF39 Chemical Properties |
| Boiling point | 309.3±30.0 °C(Predicted) | | density | 1.131±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | form | oil | | color | colorless to light brown |
| INF39 Usage And Synthesis |
| Uses | INF 39 is a NLRP3 inflammasome inhibitor. Used in the treatment of inflammatory bowel disease. | | Biochem/physiol Actions | INF39 is an orally active acrylate derivative and a non-cytotoxic INF4E analog (no toxicity at 100 μM in THP-1 cultures vs. TC50 = 65 μM with INF4E) that acts as an irreversible inhibitor against NLRP3 (NACHT, LRR and PYD domains-containing protein 3) ATPase activity (52% inhibition in 15 min by 100 μM INF39; 105 ng human NLP3 & 250 μM ATP) essential for the NLRP3 inflammasome assembly and activation. INF39 effectively decreases 5 mM (30 min) ATP-induced interleukin-1β (IL-1β) release and pyroptosis of murine bone marrow-derived macrophages in cultures (by 55-58% and 43-65%, respectively, with 1-hr 10 μM INF39 pretreatment of LPS-primed BMDM) and alleviates gut-associated inflammation in a rat model of 2,4-dinitrobenzenesulfonic acid (DNBS)-induced colitis in vivo (12.5-50 mg/kg/day in 0.2 mL olive oil p.o.). |
| INF39 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye